Participated · Series A · Aug 2026

Remepy develops Hybrid Drugs that integrate prescription medicines with personalized, AI-driven therapeutic apps to combine pharmacology with adaptive physical, cognitive, and behavioral interventions. The company partners with pharmaceutical firms to co-develop these drug–software combination products and recently announced a strategic collaboration with Merck KGaA. Remepy’s lead program, Hybridopa for Parkinson’s disease, produced encouraging Phase IIa results supported by peer‑reviewed publications and is being prepared for a global Phase III trial expected to begin in Q4 2026. The Series A financing and existing investor base have brought total capital raised to $62 million, providing funds to expand the company’s pipeline, platform, and pharmaceutical partnerships. Remepy positions its approach within emerging FDA frameworks for drug‑software combination products and aims to create new IP and lifecycle-management opportunities for partner drugs.

Participated · Series A · Mar 2026

Dimer Health builds a post-discharge care model that pairs AiME, a proprietary clinician-developed clinical AI system, with licensed clinicians called Transitionists who manage the full episode of care from hospital discharge through recovery. AiME engages patients in real time, analyzes symptoms against medical history and medications, and detects early risk signals, escalating to a Transitionist when intervention is needed. The company reports operating across eight states with partnerships spanning 28 healthcare facilities and a regional payor, and has shown up to a 67% reduction in unnecessary readmissions, a net promoter score above 90, and 30% quarter-over-quarter revenue growth for four consecutive quarters. Founded in 2023 and headquartered in Florham Park, New Jersey, Dimer Health aims to expand its Transitionist model, deepen system and payor partnerships, and improve AiME’s predictive and automation capabilities to modernize discharge processes.

Participated · Seed · Sep 2025

Leo AI, founded in 2013 by Dr. Maor Farid and Moti Moravia, is a Cambridge, MA–based AI company focused on physical product engineering. Its core product turns sketches or short text prompts into full 3D models, enabling engineers to focus on building products. The platform aims to replace hours of manual work with instant, accurate solutions and can cut up to 70% of engineering time and cost. Engineers at companies such as Scania, HP, Siemens and Mobileye have used Leo to generate over 475K 3D concepts. The company recently raised $9.7M in Seed funding and plans to use the proceeds to expand the team, scale into new markets, and enhance product development.

Participated · Series A · May 2025

Somite.ai develops large-scale foundation models for human stem cells and a full-stack platform to accelerate discovery and optimization of cell therapies. The company’s proprietary capsule-based data generation platform produces differentiation data at approximately one‑thousandth the cost of traditional methods, enabling dense, causal datasets for training powerful predictive models. Somite combines low-cost data generation, large-scale model training, and model-driven discovery to compress development timelines for cell therapies. The company announced a collaboration with AMD Ventures to pair its platform with AMD Instinct GPUs, boosting compute for model training and exploring optimization of software tools for biological data. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone, the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. Somite is based in Boston, launched operations in January 2024, and has raised approximately $60M to date. Somite AI builds DeltaStem, a foundation-model platform and associated tools to design and optimize cell differentiation protocols for scalable human cell production. Its proprietary capsule technology generates cell state transition and signaling data at roughly 1,000x the efficiency of existing methods, which feeds DeltaStem. The company plans to use the platform to advance internal therapeutic programs including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders. Somite positions DeltaStem as a generalizable foundation model for developmental biology, aiming to deliver protocols with improved purity, scalability, and reliability. The company reported closing a Series A financing of more than $47 million to accelerate platform development and key programs. Founders and scientific leadership include Dr. Micha Breakstone and Dr. Jonathan Rosenfeld alongside noted academic co‑founders such as Olivier Pourquié, Allon Klein, Jay Shendure, and Cliff Tabin. Somite Therapeutics builds AI foundation models (AlphaStem) that generate large datasets to design and produce human tissues for cell-replacement therapies. The company focuses on developing scalable cell therapies for diseases such as diabetes, obesity, and muscular dystrophies, and its pipeline includes SMT-M01 for Duchenne muscular dystrophy and SMT-B01 for metabolic disorders. Somite plans to use generated data to iteratively improve its platform and expand therapy creation across broader indications. The team is led by founder and CEO Dr. Micha Breakstone and includes senior scientific and translational leaders and prominent academic co-founders. Financially, Somite completed a $4.8M extension of its pre-seed round, bringing total funds raised to over $10M. The new capital is earmarked to expedite data generation for AlphaStem, advance SMT-M01 toward the clinic, initiate the SMT-B01 program, and begin research with hypoimmune cell lines. Somite is a Boston, MA–based developer of AI for stem cell biology building foundation models to produce human tissue for cell therapies. Its proprietary AlphaStem AI platform generates massive datasets that improve the platform and enable therapy creation through rapid optimization cycles. The company focuses on producing cells derived from somites — including muscle, brown adipose, cartilage, bone, tendon, and dermis — to address diseases such as diabetes, obesity, and muscular dystrophies. Somite is also pioneering a computational digital twin of the embryo that draws on scRNA-Seq, scATAC-seq, and gene expression databases to mirror development and identify regulators of cell differentiation. The team combines AI and developmental biology expertise and includes CEO and co-founder Micha Breakstone alongside scientific co-founders such as Olivier Pourquie, Allon Klein, and Cliff Tabin. The company raised funding to continue development of AlphaStem and advance its platform.

Participated · Seed · Feb 2023

Founded in 2022 by the serial cybersecurity entrepreneurs behind Demisto, Los Altos-based Descope offers a visual, drag-and-drop external IAM platform that lets developers create, modify, and manage authentication and authorization journeys for end users, partners, AI agents, and MCP servers. The product includes capabilities such as a connectors ecosystem, identity federation broker, agentic identity hub, and FedRAMP High-authorized offerings, all delivered with a developer-friendly no-code/low-code interface. Descope’s platform is now used by over a thousand organizations in production, serving thousands of companies overall, saving time for tens of thousands of developers, and managing hundreds of millions of identities. The company has earned recognition from KuppingerCole, Frost & Sullivan, Gartner, Fortune’s Cyber 60, and others. With total seed funding of $88 million, Descope is well-capitalized to pursue its roadmap. The newly raised capital will fund further R&D in agentic identity, geographic expansion, and headcount growth across engineering, product, and customer experience teams.